This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain

This study has been completed.
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) ) Identifier:
First received: July 25, 2007
Last updated: January 15, 2013
Last verified: January 2013
This study will compare the efficacy and the safety of ABT-894 (1mg, 2mg or 4mg capsules) administered BID to placebo in the treatment of DNP. Another treatment arm will be Duloxetine 60mg administered once daily (QD). Approximately 275 subjects will be enrolled into the study at approximately 50 sites in both the United States and Europe. The study will be divided into the following periods: Screening/Washout (21 days) followed by a Baseline Visit, an 8-week Treatment Period and a 1-week Follow-up Visit.

Condition Intervention Phase
Diabetic Neuralgia Diabetic Neuropathies Diabetic Neuropathy, Painful Diabetic Polyneuropathy Neuralgia, Diabetic Drug: ABT-894 Drug: placebo Drug: Duloxetine Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Global, Multicenter, Randomized, Double-Blind Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain

Resource links provided by NLM:

Further study details as provided by AbbVie ( AbbVie (prior sponsor, Abbott) ):

Primary Outcome Measures:
  • Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP [ Time Frame: Change from baseline to final 24-hour average pain score ]

Secondary Outcome Measures:
  • Proportions of treatment responders; subjects who complete treatment period with 30% improvement [ Time Frame: From Baseline to final 24-hour average pain score ]
  • Mean of 24-hour worst pain severity, average of night pain, and average of morning pain measured by the 11-point Likert scale and from subject's daily diary [ Time Frame: Weekly through treatment phase ]
  • Brief Pain Inventory (BPI) (short form) including Pain Severity [ Time Frame: At each visit from Baseline to Week 8 visit ]
  • Clinician Global Impression: Severity (CGI-S) and Patient Global Impression: Change (PGI-C) [ Time Frame: At each visit from Baseline to Week 8 visit ]

Enrollment: 280
Study Start Date: August 2007
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
ABT-894 1 mg BID
Drug: ABT-894
ABT-894 1 mg capsule BID throughout treatment period
Experimental: B
ABT-894 2 mg BID
Drug: ABT-894
ABT-894 2 mg capsule BID throughout treatment period
Experimental: C
ABT-894 4 mg BID
Drug: ABT-894
ABT-894 4 mg capsule BID throughout treatment period
Placebo Comparator: D Drug: placebo
placebo capsule BID throughout the treatment period
Active Comparator: E
Duloxetine 60 mg QD
Drug: Duloxetine
Duloxetine 60 mg QD throughout treatment period


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • If female, subject is either postmenopausal for at least two (2) years or surgically sterile or is practicing at least one (1) method of birth control.
  • If female, subject must have negative results for pregnancy tests.
  • The subject must have a diagnosis of diabetes mellitus (Type 1 or Type 2) and a diagnosis of DNP.
  • Subject's DNP must be present for a minimum of six (6) months and should have begun in the feet with relative symmetrical onset.
  • Subject has an HgbA1c <= 9. Subjects who have an HgbA1c > 9 and <= 11 may be included in the study.
  • If male, the subject is surgically sterile (vasectomy), is sexually inactive, or is using a barrier method (condom) of birth control for the duration of the study and for 7 days following the last dose of study drug.

Exclusion Criteria:

  • The subject has failed previous treatment with duloxetine for DNP.
  • Subject has a diagnosis of narrow-angle glaucoma.
  • Subject has a history of an allergic reaction or intolerance to duloxetine, acetaminophen, or any other NNR agonist.
  • Subject has a diagnosis of fibromyalgia that requires treatment.
  • Subject has a functioning implanted medical device (spinal cord stimulator, intrathecal pump or peripheral nerve stimulator) for the treatment of neuropathic pain.
  • Subject has a history of seizures (febrile may be ok) or major depressive episode within the past two (2) years or major psychiatric disorder including bipolar disorder, schizophrenia or borderline personality disorder.
  • Subject has a history of myocardial infarction (MI) within six (6) months of the Screening Visit.
  • Subject has unstable angina.
  • Subject has ventricular arrhythmia requiring anti-arrhythmic therapy.
  • Subject has undergone a cardiac revascularization procedure within 30 days of Screening.
  • Subject has uncontrolled hypertension (HTN) defined as a systolic blood pressure (BP) >= 160 and/or a diastolic blood pressure (BP) >= 100 at Screening and/or Baseline.
  • Subject has a clinically significant abnormal ECG at Screening
  • Subject has an active malignancy of any type or has been diagnosed with or treated for cancer within the past 5 years.
  • Subject has a positive result for drugs of abuse at Screening with the exception of a positive result for a known prescribed medication.
  • Subject's screening laboratory results show hepatitis A, B or C.
  • Subject has a known or suspected history of Human Immunodeficiency Virus (HIV).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00507936

  Show 49 Study Locations
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Study Director: Wolfram Nothaft, MD AbbVie
  More Information

Responsible Party: AbbVie (prior sponsor, Abbott) Identifier: NCT00507936     History of Changes
Other Study ID Numbers: M06-850
2007-001139-71 ( EudraCT Number )
Study First Received: July 25, 2007
Last Updated: January 15, 2013

Keywords provided by AbbVie ( AbbVie (prior sponsor, Abbott) ):
Diabetic Neuropathy
Diabetic Polyneuropathy
Diabetic Neuropathies
Diabetic Neuralgia

Additional relevant MeSH terms:
Diabetic Neuropathies
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Duloxetine Hydrochloride
Serotonin and Noradrenaline Reuptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Antidepressive Agents
Psychotropic Drugs
Dopamine Agents processed this record on September 20, 2017